Tuesday - December 23, 2025
Enhertu Granted Breakthrough Therapy Designation in the US as Post-Neoadjuvant Therapy for Patients With HER2-Positive Early Breast Cancer
December 23, 2025
WILMINGTON, Delaware, Dec. 23 (TNSjou) -- AstraZeneca, a biopharmaceutical company, issued the following news release:

* * *

ENHERTU(R) (fam-trastuzumab deruxtecan-nxki) granted Breakthrough Therapy Designation in the US as post-neoadjuvant therapy for patients with HER2-positive early breast cancer

Tenth Breakthrough Therapy Designation for AstraZeneca and Daiichi Sankyo's

ENHERTU with the latest based on DESTINY-Breast05 Phase III trial . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products